Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REVCO BANISHES ODD LOT DISSIDENTS IN LATEST ROUND OF FEUD

Executive Summary

REVCO BANISHES ODD LOT DISSIDENTS IN LATEST ROUND OF FEUD between Revco top management and Odd Lot principles Bernard Marden and Isaac Perlmutter, former chairman and president, respectively, of the Revco subsidiary. In a Feb. 4 press release announcing the appointment of new management to head Odd Lot, Revco reported that Marden and Perlmutter's "connections with the company have been terminated." However, the two Odd Lot dissidents still hold the 12% block of Revco outstanding shares they received from the sale of Odd Lot last April. The firing of the two Odd Lot officers is the epilogue to last summer's challenge to Revco Chairman Sidney Dworkin's leadership of the chain by the Odd Lot dissidents. Using their 12% share of Revco stock as leverage, Marden and Perlmutter threatened to force a proxy battle or an unfriendly takeover of the chain unless Dworkin agreed to step down. A prolonged struggle for control of Revco was averted in September when shareholders authorized the chain's management to exercise its right of first refusal to purchase the dissidents' shares if the shares are offered by Marden and Perlmutter. Current Odd Lot Exec VP Stephen Adler and Leo Kaye, formerly head of his own firm, Americore, will replace Marden and Perlmutter, "effective immediately," Revco said. Under the new Odd Lot management arrangement, Adler, who has been with Odd Lot for five years, will retain his exec VP title and "will have responsibility for retail operations," the Revco release notes. Kay, who comes to Revco with "more than 20 years of experience buying promotional merchandise from mfrs., retail chains and importers and selling to mass discount chains," will head Odd Lot's Tangible whsle. div., Revco said. The Revco board is apparently making use of Odd Lot's recent weak performance to justify the firing of the two dissident shareholders. "With this new management plan in place, we have an excellent opportunity to return Odd Lot to sound, profitable operation," Dworkin said. In Revco's most recent financial report for the second quarter (ended Nov. 17) of FY 1985, the chain partly attributed a drop in net earnings "to an unexpectedly poor performance by Odd Lot." Second quarter sales for the Tangible div. fell 25%, while like-store volume from Odd Lot's retail div. slipped 5%, Revco noted at the time. Revco earnings were also hurt by higher interest expenses and inventory financing costs primarily to cover large purchases of close-out merchandise by Odd Lot.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS007848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel